Currently, there are 2.15M common shares owned by the public and among those 2.05M shares have been available to trade.
The company’s stock has a 5-day price change of 42.50% and -30.91% over the past three months. CYCC shares are trading -57.30% year to date (YTD), with the 12-month market performance down to -89.87% lower. It has a 12-month low price of $0.75 and touched a high of $11.34 over the same period. CYCC has an average intraday trading volume of 68.46K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 21.57%, 7.02%, and -38.25% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) shares accounts for 10.66% of the company’s 2.15M shares outstanding.
It has a market capitalization of $2.45M and a beta (3y monthly) value of 0.52. The earnings-per-share (ttm) stands at -$17.52. Price movements for the stock have been influenced by the stock’s volatility, which stands at 30.69% over the week and 13.38% over the month.
Earnings per share for the fiscal year are expected to increase by 88.30%, and 36.42% over the next financial year.
Looking at the support for the CYCC, a number of firms have released research notes about the stock. Oppenheimer stated their Outperform rating for the stock in a research note on July 18, 2022, with the firm’s price target at $17. ROTH Capital coverage for the Cyclacel Pharmaceuticals Inc (CYCC) stock in a research note released on April 27, 2020 offered a Buy rating with a price target of $24. Ladenburg Thalmann was of a view on September 07, 2018 that the stock is Buy, while H.C. Wainwright gave the stock Buy rating on October 16, 2015, issuing a price target of $5. Roth Capital on their part issued Buy rating on February 04, 2010.
